The new results led to the South African Government suspending use of AstraZeneca in their vaccination programme, as it is no longer able to stop the mutation - but could still prevent hospitalisation and fatality.
Phase Three data from the UK trial shows that Novavax still works powerfully against the UK mutation, with a less intense impact on the South African mutation at 60%.
EU leaders are investigating why AstraZeneca are not following through with the pre-agreed number of vaccines for the Member States - taking a 60% cut to the expected amount.
The São Paulo Government and Butantan Institute revealed that the Sinovac COVID-19 vaccine is 15.6% less effective than officials previously suggested.
The projects will happen in 14 Member States and the United Kingdom, with 36 million in funding to get COVID-19 plasma to patients - boosting their immune response to the virus.
The approval of the Moderna COVID vaccine in the UK comes 2 days after European medical regulators, but not a moment too soon - the death toll continues to climb, standing at 78,508 currently.
Here, Mark Clements, MD PhD, paediatric endocrinologist, clinical investigator, and chief medical officer at Glooko Inc. takes part in a Q&A regarding his perspectives on remote clinical trials and data management tools.
The Oxford and AstraZeneca vaccine trial gave an accidental half-dose to 3,000 people - but this mistake is the reason the vaccine acted as 90% efficient.
Today (20 November) Pfizer and BioNTech are sending their drug for approval to the FDA, meaning that the most vulnerable Americans could get the vaccine in December.
